Alnylam Receives Notice of Allowance for US Patent Application on RNAi Agents

According to the company, the application claims "certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates, for in vivo delivery."

Silence Therapeutics Issued Notice of Allowance for US Patent Application on Cancer Target

The target, PKN-3, is a protein kinase C-related molecule associated with the growth of cancer cells, as well as metastasis formation, and is the target for the company's phase I siRNA-based solid tumor drug Atu-027.

Stealth Spins Out miRNA-Inhibition Technology Into New Company

Concurrent with the move, the new company has also secured an undisclosed amount of seed financing that is expected to enable the new firm to complete planned in vivo proof-of-concept studies.

Asuragen Forms Collaborations to Develop FNA Version of Pancreatic Cancer miRNA Test

The test is expected to be available through Asuragen's clinical laboratory improvement amendments-certified lab in the second half of this year.

Benitec Continuation Patent Application Allowed by USPTO

The patent is derived from Benitec's key US patent, No. 6,573,099, which covers gene-expression knockdown using DNA that transcribes double-stranded RNA.

Papers of Note

RNAi- and microRNA-Related Papers Published January 2010

IP Update

USPTO Publishes Three Patents, Six Patent Applications Related to RNAi

People in the News

Palle Schelde, Thorlief Moller, John Riis Mortensen, Finn Cilius Nielsen, Ole Bitsch-Jensen, Daniel Kisner, Michael Forrest, Frank Karbe, Kenneth Galbraith, John Chiplin

In Court Filing, Alnylam, Max Planck Question UMass Ownership of Tuschl-I IP

The matter is of particular importance since UMass is the only one of the four organizations to which the IP is assigned to have licensed it to companies other than Alnylam.

NIH Awards Three Grants In January to Help Develop RNAi-based Cancer Therapies

The grants, which are all being funded by the National Cancer Institute, will specifically support efforts in prostate cancer, melanoma, and malignant solid tumors.

USPTO Allows Claims in Regulus Patent Application on miR-21

According to the company, the miRNA is linked to a variety of diseases including cancer, fibrosis, and heart disease.

MDRNA Issued Chinese Patent on Use of Nucleic Acids to Treat Cancer

The patent describes the modulation of claudins, which are proteins associated with tumor progression and metastasis.

Targeted Genetics Stock Delisted from Nasdaq

The company's common stock is now traded on the Over-The-Counter Bulletin Board.